BioRexis Pharmaceutical

BioRexis Pharmaceutical was a clinical-stage biopharmaceutical company specializing in the development of long-acting biotherapeutics. The company utilized its proprietary Trans-Rexis platform, which involves fusing therapeutic proteins or peptides to human transferrin to significantly extend their circulating half-life. This technology was designed to create "bio-better" versions of existing drugs with improved dosing schedules and efficacy profiles. BioRexis's lead candidate, BRX-0585, was a long-acting GLP-1 receptor agonist for the treatment of type 2 diabetes. The company was acquired by Pfizer in 2007 to enhance Pfizer's portfolio in metabolic diseases and biologics.